Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.6775 ^USD	+2.09%		+0.24%	-49.81%

Jul. 09	Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc	CI
Jul. 01	Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600	CI

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

April 25, 2022 at 09:00 am EDT

Progenity, Inc. announced the appointment of Paul Shabram, MBA, as Senior Vice President, Technical Operations. Mr. Shabram brings over 30 years of biotech experience leading successful development programs and commercial products while implementing novel manufacturing processes. Before joining Progenity, Mr. Shabram formed Ventana BioSciences Consulting to support developers of vaccines and cancer therapeutics.

Previously, he was the Vice President of Technical Development at Emergent Biosolutions.

Latest news about Biora Therapeutics, Inc.

Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc	Jul. 08	CI
Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600	Jul. 01	CI
Biora Therapeutics Provides Information to the Shareholders	Jun. 07	CI
Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director	Jun. 07	CI
Biora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Transcript : Biora Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024	May. 15
Earnings Flash (BIOR) BIORA THERAPEUTICS Reports Q1 Revenue $542,000	May. 15	MT
Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	Apr. 30	CI
Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	Apr. 04	CI
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	Apr. 02	CI
Top Midday Decliners	Apr. 01	MT
Transcript : Biora Therapeutics, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600	Feb. 26	CI
Transcript : Biora Therapeutics, Inc. - Special Call	Jan. 29
Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600	Jan. 08	CI
Biora Therapeutics, Inc. Progresses Research Collaboration for the BioJet Systemic Oral Delivery Platform with AstraZeneca	Jan. 02	CI
Athyrium Capital Management Engages in Discussions with Biora Therapeutics	Dec. 20	CI
Biora Therapeutics, Inc. Announces New Research Collaboration for the Biojet Systemic Oral Delivery Platform	Dec. 11	CI
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	Dec. 01	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Dec. 01	MT
Top Premarket Gainers	Dec. 01	MT
Biora Therapeutics Says FDA Cleared Application for Investigational Ulcerative Colitis Treatment; Shares Rise Pre-Bell	Dec. 01	MT
Biora Therapeutics Shares Rise 64% After FDA Clears Application for Ulcerative Colitis Treatment	Nov. 30	DJ

Chart Biora Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Companyâs pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

Sector

Biotechnology & Medical Research

Calendar

2024-07-17 - Investor Meeting - Key Opinion Leader

More about the company

Income Statement Evolution

More financial data

Ratings for Biora Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.6775 USD

Average target price

10.3 USD

Spread / Average Target

+1,420.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIORA THERAPEUTICS, INC.	-49.81%	24.35M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs